CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Rituximab for Refractory Ocular Symptoms in Myasthenia Gravis with Thyroid Eye Disease: A Case Report with Quantitative MRI Assessment
Provisionally accepted
- 1Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai 200040, China
- 2Department of Radiology, Huashan Hospital Fudan University, Shanghai 200040, China
- 3Department of Encephalopathy, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, Changchun 130017, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aims: To report a case with concurrent myasthenia gravis (MG) and thyroid eye disease (TED) showing response to rituximab (RTX) through both clinical evaluation and quantitative MRI assessment. Methods: A 31-year-old female patient with refractory ocular symptoms from concurrent MG and TED received RTX after failing multiple conventional treatments. Treatment response was evaluated through clinical scores and quantitative T2 mapping of extraocular muscles (EOMs) before and after RTX administration. Results: Following RTX treatment, the patient achieved corticosteroid-free remission by six months post-RTX, with Myasthenia Gravis Activities of Daily Living score decreasing from 5 to 0, complete resolution of ptosis, and improvement in ocular motility and exophthalmos. Quantitative T2 mapping demonstrated significant reductions in T2 relaxation times (10.6%-20.9%) across all EOM regions of interest, with decreased standard deviations indicating restored tissue homogeneity. Conclusions: This case suggests potential therapeutic benefit of RTX for refractory ocular symptoms in concurrent MG and TED. Quantitative T2 mapping revealed pathologically elevated values that normalized post-treatment, providing preliminary objective evidence of treatment response. As a single case, the relative contributions of MG versus TED pathology cannot be definitively separated. Integrating clinical assessment with quantitative T2 mapping may offer an objective approach for monitoring treatment response in such complex dual autoimmune disorders.
Keywords: Myasthenia Gravis, rituximab, Thyroid eye disease, ocular symptoms, Magnetic Resonance Imaging
Received: 01 Oct 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 He, Li, Wang, Wang, Yan, Luo, Zhao and Xi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianying Xi, xijianying@fudan.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.